The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease

American Journal of Nephrology

Volumn 27, Issue 5, 2007, Pages 435-440

  Talaat, Khaled M ^a   El Sheikh, Amira R ^b  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b Zagazig University   (Egypt)

Author keywords

Angiotensin; Chronic kidney disease; Hypertension; Uric acid

Indexed keywords

ALLOPURINOL; CREATININE; FOSINOPRIL; LOSARTAN; TRANSFORMING GROWTH FACTOR BETA; URIC ACID;

ADULT; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE EXACERBATION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY DYSFUNCTION; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; TRANSFORMING GROWTH FACTOR BETA URINARY EXCRETION; URIC ACID BLOOD LEVEL; WITHDRAWAL SYNDROME;

ADULT; ALLOPURINOL; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; HYPERURICEMIA; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA1;

EID: 34748901886     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000105142     Document Type: Article

References (34)

1. Mahomed FA: On chronic Bright's disease and its essential symptoms. Lancet 1879;i:399-401.
2. Puig JG, Ruilope LM: Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999;17:869-872.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-2572.
4. Ohno I, Hosoya T, Gomi H, Ichida K, Okabe H, Hikita M: Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 2001;87:333-339.
5. Syrjanen J, Mustonen J, Pasternack A: Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000;15:34-42.
6. Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al: Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J Am Soc Nephrol 2005;16:791-799.
7. Mazzali M, Hughes J, Kim YG, et al: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-1106.
8. Mazzali M, Kanellis J, Han L, Feng L, et al: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-F997.
9. Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al: Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002;283:1105-1110.
10. Nakagawa T, Mazzali M, Kang DH, Kanellis J, et al: Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003;23:2-7.
11. Culleton BF, Larson MG, Kannel WB, Levy D: Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7-13.
12. Pacher P, Nivorozhkin A, Szabo C: Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006;58:87-114.
13. Johnson RJ, Kang D-H, Feig D, et al: Is there a pathogenetic role for uric acid in hypertension, cardiovascular and renal disease. Hypertension 2002;41:1183-1190.
14. Gonick HC, Behari JR: Is lead exposure the principal cause of essential hypertension? Med Hypotheses 2002;59:239-246.
15. Border WA, Noble NA: Transforming growth factor-β in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
16. Yamamoto T, Noble NA, Miller DE, Border WA: Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis. Kidney Int 1994;45:916-927.
17. Yamamoto T, Noble NA, Cohen AH, et al: Expression of TGF-β isoforms in human glomerular diseases. Kidney Int 1996;49:461-469.
18. Bodi I, Kimmel PL, Abraham AA, Svetkey LP, Klotman PE, Kopp JB: Renal TGF-β in HIV-associated kidney diseases. Kidney Int 1997;51:1568-1577.
19. Niemir ZI, Stein H, Noronha IL, et al: PDGF and TGF-β contribute to the natural course of human IgA glomerulonephritis. Kidney Int 1995;48:1530-1541.
20. Levey AS, Coresh J, Balk E: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification and stratification. Ann Intern Med 2003;139:137-147.
21. Eknoyan G, Hostetter T, Bakris GL, et al: Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). Am J Kidney Dis 2003;42:617-622.
22. Ellis D, Forrest KY, Erbey J, Orchard TJ: Urinary measurement of transforming growth factor-beta and type IV collagen as new markers of renal injury: application in diabetic nephropathy. Clin Chem 1998;44:950-956.
23. Alderman M, Aiyer KJ: Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004;20:369-379.
24. Waring WS, Webb DJ, Maxwell SRJ: Effect of local hyperuricemia on endothelial function in the human forearm vascular bed. Br J Clin Pharmacol 2000;49:511.
25. Kanabrocki EL, Third JL, Ryan MD, Nemchausky BA, Shirazi P, Scheving LE, McCormick JB, Hermida RC, Bremner WF, Hoppensteadt DA, Fareed J, Olwin JH: Circadian relationship of serum uric acid and nitric oxide. JAMA 2000;283:2240-2241.
26. Saito I, Saruta T, Kondo K, et al: Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriatr Soc 1978;26:241-247.
27. Feig DI, Johnson RJ: Hyperuricemia in childhood primary hypertension. Hypertension 2003;42:247-252.
28. Kang D-H, Park S-K, Lee I-K, Johnson RJ: Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005;16:3553-3562.
29. Netea MG, Kullberg BJ, Block WL, Netea RT, van der Meer JW: The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 1997;89:577-582.
30. Rao GN, Corson MA, Berk BC: Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet derived growth factor A-chain expression. J Biol Chem 1991;266:8604-8608.
31. Han L, Kanellis J, Li P, Feng L, et al: The evidence for a functional organic anion transporter in vascular smooth muscle cells. American Society of Nephrology 35th Annual Meeting and Scientific Exposition. Program and Abstracts 329A, Philadelphia, 2002.
32. Kanellis J, Watanabe S, Li JH, et al: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003;41:1287-1293.
33. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B: Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002;346:913-923.
34. Kang DH, Seoh Y, Yoon K-I: A possible link between hyperuricemia and systemic inflammatory reaction as a mechanism of endothelial dysfunction in chronic renal failure. American Society of Nephrology 35th Annual Meeting and Scientific Exposition. Program and Abstracts 466A, Philadelphia, 2002.